184 related articles for article (PubMed ID: 36041055)
1. S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression.
Zhong C; Niu Y; Liu W; Yuan Y; Li K; Shi Y; Qiu Z; Li K; Lin Z; Huang Z; Zuo D; Yang Z; Liao Y; Zhang Y; Wang C; Qiu J; He W; Yuan Y; Li B
Adv Sci (Weinh); 2022 Oct; 9(30):e2202206. PubMed ID: 36041055
[TBL] [Abstract][Full Text] [Related]
2. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
4. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review.
Zhao Y; Cai G; Zhou L; Liu L; Qi X; Bai M; Li Y; Fan D; Han G
Asia Pac J Clin Oncol; 2013 Dec; 9(4):357-64. PubMed ID: 23714021
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
Qu K; Yan Z; Wu Y; Chen Y; Qu P; Xu X; Yuan P; Huang X; Xing J; Zhang H; Liu C; Zhang J
J Gastroenterol Hepatol; 2015 May; 30(5):925-32. PubMed ID: 25641377
[TBL] [Abstract][Full Text] [Related]
7. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
[TBL] [Abstract][Full Text] [Related]
10. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma].
Schneeweiß S; Horger M; Ketelsen D; Ioanoviciu SD
Rofo; 2015 Feb; 187(2):79-82. PubMed ID: 25629286
[No Abstract] [Full Text] [Related]
11. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
13. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
14. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
[TBL] [Abstract][Full Text] [Related]
15. HBx-induced S100A9 in NF-κB dependent manner promotes growth and metastasis of hepatocellular carcinoma cells.
Duan L; Wu R; Zhang X; Wang D; You Y; Zhang Y; Zhou L; Chen W
Cell Death Dis; 2018 May; 9(6):629. PubMed ID: 29795379
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
19. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
20. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways.
Wu R; Duan L; Cui F; Cao J; Xiang Y; Tang Y; Zhou L
Exp Cell Res; 2015 Jun; 334(2):228-38. PubMed ID: 25907296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
